SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: cur who wrote (54)8/11/1997 6:55:00 PM
From: scaram(o)uche   of 579
 
The scope of the collaboration had been cut at the previous renewal. At the annual meeting, Dr. Comer stressed that SIBI was focussed on a receptor subtype that they believed may be involved in migraine, and which had been pulled back to SIBI in the last renewal. The focus at the meeting was on 1508Y, the "53" series, and the Ciba (Novartis) and BMY programs. I got the idea that the Lilly deal was dead in the water, and now it is.

So, for me, it's neutral. It certainly isn't a positive, IMO.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News